Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double Blind, Randomized, Vehicle Controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of CD 07223 1.5% Topical Gel in Impetigo

Next Previous
Trial Profile

A Multicenter, Double Blind, Randomized, Vehicle Controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of CD 07223 1.5% Topical Gel in Impetigo

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 09 Oct 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Auriclosene (Primary)
  • Indications Impetigo; Staphylococcal infections
  • Focus Registrational; Therapeutic Use
  • Sponsors NovaBay Pharmaceuticals

    • Most Recent Events

    • 01 Aug 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Jun 2013 Galderma expects to complete enrolment in the third quarter of 2013, and top-line results are expected in the fourth quarter of 2013, according to a NovaBay Pharmaceuticals media release.
    • 05 Feb 2013 Enrollment has been initiated in the South African arm of this trial, according to a NovaBay Pharmaceuticals media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top